Mechanisms of vascular disease

Scleroderma: From Pathogenesis to Comprehensive Management

Volumn , Issue , 2012, Pages 227-246

  Kahaleh, Bashar ^a   Mulligan Kehoe, Mary Jo ^b  

^a UNIVERSITY OF TOLEDO MEDICAL CENTER   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Autoantibody; Coagulation; Endothelial cell; Endothelin; Microangiopathy; Platelet; ROS; Vascular disease

Indexed keywords

EID: 85020706272     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4419-5774-0_19     Document Type: Chapter

References (218)

1. Fleischmajer R, Perlish JS, Shaw KV, Pirozzi DJ. Skin capillary changes in early systemic scleroderma. Electron microscopy and "in vitro" autoradiography with tritiated thymidine. Arch Dermatol. 1976;112:1553-7.
2. Grassi W, Core P, Carlino G, Blasetti P, Cervini M. Labial capillary microscopy in systemic sclerosis. Ann Rheum Dis. 1993;52:564-9.
3. Fleischmajer R, Perlish JS. Capillary alterations in scleroderma. J Am Acad Dermatol. 1980;2:161-70.
4. Sgnonc R, Gruschwitz MS, Dietrich H, et al. Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. J Clin Invest. 1996;98:785-92.
5. Chen F, Eriksson P, Kimura T, et al. Apoptosis and angiogenesis are induced in the unstable coronary atherosclerotic plaque. Coronary Artery Dis. 2005;16(3):191-7.
6. Mitra D, Steiner M, Staiano-Coico L, Jaffe E. Plasma from patients with idiopathic and human immunodeficiency virus-associated thrombotic thrombocytopenic purpura induces apoptosis in microvascular endothelial cells. Blood. 1996;87(8):3245-54.
7. Francisco LM, Sauter B, Roy P, Silverstein RL, Bhardwaj N. Immature dendritic cells phagocytose apoptotic T lymphocytes. J Exp Med. 1998;88:1359-68.
8. Greeno EW, Bach RR, Moldow CF. Apoptosis is associated with increased cell surface tissue factor procoagulant activity. Lab Invest. 1996;75(2):281-9.
9. Tsuji S, Kaji K, Nagasawa S. Activation of the alternative pathway of human complement by apoptotic human umbilical vein endothelial cells. J Biochem. 1994;116(4):794-800.
10. Fleischmajer R, Perlish JS. [3H] thymidine labeling of dermal endothelial cells in scleroderma. J Invest Dermatol. 1977;69:379-82.
11. Rodnan GP, Myerowitz RL, Justh GO. Morphologic changes in the digital arteries of patients with progressive systemic sclerosis (scleroderma) and Raynaud's phenomenon. Medicine. 1980;59:393-408.
12. Youssef P, Englert H, Bertouch J. Large vessel occlusive disease associated with CREST syndrome and scleroderma. Ann Rheum Dis. 1993;52:464-6.
13. Pandey JP, LeRoy EC. Human cytomegalovirus and the vasculopathies of autoimmune diseases (especially scleroderma), allograft rejection, and coronary restenosis. Arthritis Rheum. 1998;41(1):10-5.
14. Cannon PJ, Hassar M, Case DB, Casarella WJ, Sommers SC, LeRoy EC. The relationship of hypertension and renal failure in scleroderma (progressive systemic sclerosis) to structural and functional abnormalities of the renal cortical circulation. Medicine. 1974;53(1):1-46.
15. Prescott RJ, Freemont AJ, Jones CJ, Hoyland J, Fielding P. Sequential dermal microvascular and perivascular changes in the development of scleroderma. J Pathol. 1992;166(3):255-63.
16. Lippton HL, Hauth TA, Summer WR, Hyman AL. Endothelin produces pulmonary vasoconstriction and systemic vasodilation. J Appl Physiol. 1989;66(2):1008-12.
17. Vancheeswaran R, Azam A, Black C, Dashwood MR. Localization of endothelin-1 and its binding sites in scleroderma skin. J Rheumatol. 1994;21(7):1268-76.
18. Vancheeswaran R, Magoulas T, Efrat G, Wheeler-Jones C, Olsen I, Penny R, Black CM. Circulating endothelin-1 levels in systemic sclerosis subsets-a marker of fibrosis or vascular dysfunction? J Rheumatol. 1994;21(10):1838-44.
19. Cambrey AD, Harrison NK, Dawes KE, Southcott AM, Black CM, du Bois RM, Laurent GJ, McAnulty RJ. Increased levels of endothelin-1 in bronchoalveolar lavage fluid from patients with systemic sclerosis contribute to fibroblast mitogenic activity in vitro. Am J Respir Cell Mol Biol. 1994;11(4):439-45.
20. Kawaguchi Y, Suzuki K, Hara M, Hidaka T, Ishizuka T, Kawagoe M, Nakamura H. Increased endothelin-1 production in fibroblasts derived from patients with systemic sclerosis. Ann Rheum Dis. 1994;53(8):506-10.
21. Morelli S, Ferri C, Di Francesco L, Baldoncini R, Carlesimo M, Bottoni U, Properzi G, Santucci A. Plasma endothelin-1 levels in patients with systemic sclerosis: influence of pulmonary or systemic arterial hypertension. Ann Rheum Dis. 1995;54(9):730-4.
22. Morelli S, Ferri C, Polettini E, Bellini C, Gualdi GF, Pittoni V, Valesini G, Santucci A. Plasma endothelin-1 levels, pulmonary hypertension, and lung fibrosis in patients with systemic sclerosis. Am J Med. 1995;99(3):255-60.
23. Kasturi KN, Shibata S, Muryoi T, Bona CA. Tight-skin mouse an experimental model for scleroderma. Int Rev Immunol. 1994;11(3):253-71.
24. Richard V, Solans V, Favre J, Henry JP, Lallemand F, Thuillez C, Marie I. Role of endogenous endothelin in endothelial dysfunction in murine model of systemic sclerosis: tight skin mice 1. Fundam Clin Pharmacol. 2008;22(6):649-55.
25. Ignarro LJ. Biosynthesis and metabolism of endothelium-derived nitric oxide. Annu Rev Pharmacol Toxicol. 1990;30:535-60.
26. Ignarro LJ. Endothelium-derived nitric oxide: actions and properties. FASEB J. 1989;3(1):31-6.
27. Agostoni A, Marasini B, Biondi ML, Bassani C, Cazzaniga A, Bottasso B, Cugno M. L-arginine therapy in Raynaud's phenomenon? Int J Clin Lab Res. 1991;21(2):202-3.
28. Cailes J, Winter S, du Bois RM, Evans TW. Defective endothelially mediated pulmonary vasodilation in systemic sclerosis. Chest. 1998;114(1):178-84.
29. Livi R, Teghini L, Generini S, Matucci-Cerinic M. The loss of endothelium-dependent vascular tone control in systemic sclerosis. Chest. 2001;119(2):672-3.
30. Matucci-Cerinic M, Pietrini U, Marabini S. Local venomotor response to intravenous infusion of substance P and glyceryl trinitrate in systemic sclerosis. Clin Exp Rheumatol. 1990;8(6):561-5.
31. Cotton SA, Herrick AL, Jayson MI, Freemont AJ. Endothelial expression of nitric oxide synthases and nitrotyrosine in systemic sclerosis skin. J Pathol. 1999;189(2):273-8.
32. Dooley A, Gao B, Bradley N, Abraham DJ, Black CM, Jacobs M, Bruckdorfer KR. Abnormal nitric oxide metabolism in systemic sclerosis:increased levels of nitrated proteins and asymmetric dimethylarginine. Rheumatology (Oxford). 2006;45(6):676-84.
33. Mendall MA, Goggin PM, Molineaux N, Levy J, Toosy T, Strachan D, Camm AJ, Northfield TC. Relation of Helicobacter pylori infection and coronary heart disease. Br Heart J. 1994;71(5):437-9.
34. Gasbarrini A, Massari I, Serricchio M, Tondi P, De Luca A, Franceschi F, Ojetti V, Dal Lago A, Flore R, Santoliquido A, Gasbarrini G, Pola P. Helicobacter pylori eradication ameliorates primary Raynaud's phenomenon. Dig Dis Sci. 1998;43(8):1641-5.
35. Aragona P, Magazzu G, Macchia G, Bartolone S, Di Pasquale G, Vitali C, Ferreri G. Presence of antibodies against Helicobacter pylori and its heat-shock protein 60 in the serum of patients with Sjogren's syndrome. J Rheumatol. 1999;26(6):1306-11.
36. Savarino V, Sulli A, Zentilin P, Raffaella Mele M, Cutolo M. No evidence of an association between Helicobacter pylori infection and Raynaud phenomenon. Scand J Gastroenterol. 2000;35(12):1251-4.
37. Sulli A, Seriolo B, Savarino V, Cutolo M. Lack of correlation between gastric Helicobacter pylori infection and primary or secondary Raynaud's phenomenon in patients with systemic sclerosis. J Rheumatol. 2000;27(7):1820-1.
38. Pandey JP, LeRoy EC. Human cytomegalovirus and the vasculopathies of autoimmune diseases (especially scleroderma), allograft rejection, and coronary restenosis. Arthritis Rheum. 1998;41(1):10-5.
39. Vaughan JH, Shaw PX, Nguyen MD, Medsger Jr TA, Wright TM, Metcalf JS, Leroy EC. Evidence of activation of 2 herpesviruses, Epstein-Barr virus and cytomegalovirus, in systemic sclerosis and normal skins. J Rheumatol. 2000;27(3):821-3.
40. Neidhart M, Kuchen S, Distler O, Bruhlmann P, Michel BA, Gay RE, Gay S. Increased serum levels of antibodies against human cytomegalovirus and prevalence of autoantibodies in systemic sclerosis. Arthritis Rheum. 1999;42(2):389-92.
41. Presti RM, Pollock JL, Dal Canto AJ, O'Guin AK, Virgin HWt. Interferon gamma regulates acute and latent murine cytomegalovirus infection and chronic disease of the great vessels. J Exp Med. 1998;188(3):577-88.
42. Zhou YF, Shou M, Harrell RF, Yu ZX, Unger EF, Epstein SE. Chronic non-vascular cytomegalovirus infection: effects on the neointimal response to experimental vascular injury. Cardiovasc Res. 2000;45(4):1019-25.
43. Hamamdzic D, Harley RA, Hazen-Martin D, LeRoy EC. MCMV induces neointima in IFN-gammaR-/-mice: intimal cell apoptosis and persistent proliferation of myofibroblasts. BMC Musculoskelet Disord. 2001;2:3.
44. Ferri C, Longombardo G, Azzi A, Zakrzewska K. Parvovirus B19 and systemic sclerosis. Clin Exp Rheumatol. 1999;17(2):267-8.
45. Magro CM, Nuovo G, Ferri C, Crowson AN, Giuggioli D, Sebastiani M. Parvoviral infection of endothelial cells and stromal fibroblasts:a possible pathogenetic role in scleroderma. J Cutan Pathol. 2004;31(1):43-50.
46. Zakrzewska K, Corcioli F, Carlsen KM, Giuggioli D, Fanci R, Rinieri A, Ferri C, Azzi A. Human parvovirus B19 (B19V) infection in systemic sclerosis patients. Intervirology. 2009;52(5):279-82.
47. Drenk F, Deicher HR. Pathophysiological effects of endothelial cytotoxic activity derived from sera of patients with progressive systemic sclerosis. J Rheumatol. 1988;15(3):468-74.
48. Holt CM, Lindsey N, Moult J, Malia RG, Greaves M, Hume A, Rowell NR, Hughes P. Antibody-dependent cellular cytotoxicity of vascular endothelium: characterization and pathogenic associations in systemic sclerosis. Clin Exp Immunol. 1989;78(3):359-65.
49. Penning CA, Cunningham J, French MA, Harrison G, Rowell NR, Hughes P. Antibody-dependent cellular cytotoxicity of human vascular endothelium in systemic sclerosis. Clin Exp Immunol. 1984;57(3):548-56.
50. Sgonc R, Gruschwitz MS, Boeck G, Sepp N, Gruber J, Wick G. Endothelial cell apoptosis in systemic sclerosis is induced by antibodydependent cell-mediated cytotoxicity via CD95. Arthritis Rheum. 2000;43(11):2550-62.
51. Trapani JA. Dual mechanisms of apoptosis induction by cytotoxic lymphocytes. Int Rev Cytol. 1998;182:111-92.
52. Kahaleh MB, Leroy EC. Endothelial injury in scleroderma. A protease mechanism. J Lab Clin Med. 1983;101(4):553-60.
53. Kahaleh MB, Fan PS. Mechanism of serum-mediated endothelial injury in scleroderma: identification of a granular enzyme in scleroderma skin and sera. Clin Immunol Immunopathol. 1997;83(1):32-40.
54. Mullbacher A, Waring P, Tha Hla R, Tran T, Chin S, Stehle T, Museteanu C, Simon MM. Granzymes are the essential downstream effector molecules for the control of primary virus infections by cytolytic leukocytes. Proc Natl Acad Sci USA. 1999;96(24):13950-5.
55. Muller U, Sobek V, Balkow S, Holscher C, Mullbacher A, Museteanu C, Mossmann H, Simon MM. Concerted action of perforin and granzymes is critical for the elimination of Trypanosoma cruzi from mouse tissues, but prevention of early host death is in addition dependent on the FasL/Fas pathway. Eur J Immunol. 2003;33(1):70-8.
56. Smyth MJ, McGuire MJ, Thia KY. Expression of recombinant human granzyme B. A processing and activation role for dipeptidyl peptidase I. J Immunol. 1995;154(12):6299-305.
57. Browne KA, Blink E, Sutton VR, Froelich CJ, Jans DA, Trapani JA. Cytosolic delivery of granzyme B by bacterial toxins: evidence that endosomal disruption, in addition to transmembrane pore formation, is an important function of perforin. Mol Cell Biol. 1999;19(12):8604-15.
58. Buzza MS, Zamurs L, Sun J, Bird CH, Smith AI, Trapani JA, Froelich CJ, Nice EC, Bird PI. Extracellular matrix remodeling by human granzyme B via cleavage of vitronectin, fibronectin, and laminin. J Biol Chem. 2005;280(25):23549-58.
59. Mulligan-Kehoe MJ, Drinane MC, Mollmark J, Casciola-Rosen L, Hummers LK, Hall A, Rosen A, Wigley FM, Simons M. Antiangiogenic plasma activity in patients with systemic sclerosis. Arthritis Rheum. 2007;56(10):3448-58.
60. Sasaki T, Larsson H, Tisi D, Claesson-Welsh L, Hohenester E, Timpl R. Endostatins derived from collagens XV and XVIII differ in structural and binding properties, tissue distribution and anti-angiogenic activity. J Mol Biol. 2000;301(5):1179-90.
61. Maeshima Y, Sudhakar A, Lively JC, Ueki K, Kharbanda S, Kahn CR, Sonenberg N, Hynes RO, Kalluri R. Tumstatin, an endothelial cellspecific inhibitor of protein synthesis. Science. 2002;295(5552):140-3.
62. Kamphaus GD, Colorado PC, Panka DJ, Hopfer H, Ramchandran R, Torre A, Maeshima Y, Mier JW, Sukhatme VP, Kalluri R. Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth. J Biol Chem. 2000;275(2):1209-15.
63. Cao Y, Ji RW, Davidson D, Schaller J, Marti D, Sohndel S, McCance SG, O'Reilly MS, Llinas M, Folkman J. Kringle domains of human angiostatin. Characterization of the anti-proliferative activity on endothelial cells. J Biol Chem. 1996;271(46):29461-7.
64. Ferrara N, Clapp C, Weiner R. The 16K fragment of prolactin specifically inhibits basal or fibroblast growth factor stimulated growth of capillary endothelial cells. Endocrinology. 1991;129(2):896-900.
65. Staton CA, Lewis CE. Angiogenesis inhibitors found within the haemostasis pathway. J Cell Mol Med. 2005;9(2):286-302.
66. Hebbar M, Peyrat JP, Hornez L, Hatron PY, Hachulla E, Devulder B. Increased concentrations of the circulating angiogenesis inhibitor endostatin in patients with systemic sclerosis. Arthritis Rheum. 2000;43(4):889-93.
67. Hummers LK, Hall A, Wigley FM, Simons M. Abnormalities in the regulators of angiogenesis in patients with scleroderma. J Rheumatol. 2009;36(3):576-82.
68. Casciola-Rosen LA, Anhalt G, Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med. 1994;179(4):1317-30.
69. Sercarz EE, Lehmann PV, Ametani A, Benichou G, Miller A, Moudgil K. Dominance and crypticity of T cell antigenic determinants. Annu Rev Immunol. 1993;11:729-66.
70. Zhou Z, Menard HA. Autoantigenic posttranslational modifications of proteins: does it apply to rheumatoid arthritis? Curr Opin Rheumatol. 2002;14(3):250-3.
71. Izquierdo M, Grandien A, Criado LM, Robles S, Leonardo E, Albar JP, de Buitrago GG, Martinez AC. Blocked negative selection of developing T cells in mice expressing the baculovirus p35 caspase inhibitor. EMBO J. 1999;18(1):156-66.
72. Andrade F, Roy S, Nicholson D, Thornberry N, Rosen A, Casciola-Rosen L. Granzyme B directly and efficiently cleaves several downstream caspase substrates: implications for CTL-induced apoptosis. Immunity. 1998;8(4):451-60.
73. Casciola-Rosen L, Andrade F, Ulanet D, Wong WB, Rosen A. Cleavage by granzyme B is strongly predictive of autoantigen status: implications for initiation of autoimmunity. J Exp Med. 1999;190(6):815-26.
74. Schachna L, Wigley FM, Morris S, Gelber AC, Rosen A, Casciola-Rosen L. Recognition of Granzyme B-generated autoantigen fragments in scleroderma patients with ischemic digital loss. Arthritis Rheum. 2002;46(7):1873-84.
75. Youinou P, Revelen R, Bordron A. Is antiendothelial cell antibody the murder weapon in systemic sclerosis? Clin Exp Rheumatol. 1999;17(1):35-6.
76. Hill MB, Phipps JL, Cartwright RJ, Milford Ward A, Greaves M, Hughes P. Antibodies to membranes of endothelial cells and fibroblasts in scleroderma. Clin Exp Immunol. 1996;106(3):491-7.
77. Negi VS, Tripathy NK, Misra R, Nityanand S. Antiendothelial cell antibodies in scleroderma correlate with severe digital ischemia and pulmonary arterial hypertension. J Rheumatol. 1998;25(3):462-6.
78. Garcia de la Pena-Lefebvre P, Chanseaud Y, Tamby MC, Reinbolt J, Batteux F, Allanore Y, Kahan A, Meyer O, Benveniste O, Boyer O, Guillevin L, Boissier MC, Mouthon L. IgG reactivity with a 100-kDa tissue and endothelial cell antigen identified as topoisomerase 1 distinguishes between limited and diffuse systemic sclerosis patients. Clin Immunol. 2004;111(3):241-51.
79. Tamby MC, Chanseaud Y, Humbert M, Fermanian J, Guilpain P, Garcia-de-la-Pena-Lefebvre P, Brunet S, Servettaz A, Weill B, Simonneau G, Guillevin L, Boissier MC, Mouthon L. Anti-endothelial cell antibodies in idiopathic and systemic sclerosis associated pulmonary arterial hypertension. Thorax. 2005;60(9):765-72.
80. Sgonc R, Gruschwitz MS, Dietrich H, Recheis H, Gershwin ME, Wick G. Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. J Clin Invest. 1996;98(3):785-92.
81. Worda M, Sgonc R, Dietrich H, Niederegger H, Sundick RS, Gershwin ME, Wick G. In vivo analysis of the apoptosis-inducing effect of anti-endothelial cell antibodies in systemic sclerosis by the chorionallantoic membrane assay. Arthritis Rheum. 2003;48(9):2605-14.
82. Bordron A, Dueymes M, Levy Y, Jamin C, Leroy JP, Piette JC, Shoenfeld Y, Youinou PY. The binding of some human antiendothelial cell antibodies induces endothelial cell apoptosis. J Clin Invest. 1998;101(10):2029-35.
83. Tan FK, Arnett FC, Reveille JD, Ahn C, Antohi S, Sasaki T, Nishioka K, Bona CA. Autoantibodies to fibrillin 1 in systemic sclerosis: ethnic differences in antigen recognition and lack of correlation with specific clinical features or HLA alleles. Arthritis Rheum. 2000;43(11):2464-71.
84. Kahaleh MB, Sherer GK, LeRoy EC. Endothelial injury in scleroderma. J Exp Med. 1979;149(6):1326-35.
85. Mulligan-Kehoe MJ, Simons M. Current concepts in normal and defective angiogenesis: implications for systemic sclerosis. Curr Rheumatol Rep. 2007;9(2):173-9.
86. Al-Dhaher FF, Pope JE, Ouimet JM. Determinants of morbidity and mortality of systemic sclerosis in Canada. Semin Arthritis Rheum. 2010;39(4):269-77.
87. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis. 2007;66(7):940-4.
88. Mathai SC, Hummers LK, Champion HC, Wigley FM, Zaiman A, Hassoun PM, Girgis RE. Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease. Arthritis Rheum. 2009;60(2):569-77.
89. Birukov KG. Cyclic stretch, reactive oxygen species, and vascular remodeling. Antioxid Redox Signal. 2009;11(7):1651-67.
90. Grote K, Flach I, Luchtefeld M, Akin E, Holland SM, Drexler H, Schieffer B. Mechanical stretch enhances mRNA expression and proenzyme release of matrix metalloproteinase-2 (MMP-2) via NAD(P)H oxidase-derived reactive oxygen species. Circ Res. 2003;92(11):e80-6.
91. McCord JM. Oxygen-derived free radicals in postischemic tissue injury. N Engl J Med. 1985;312(3):159-63.
92. Riccieri V, Spadaro A, Fuksa L, Firuzi O, Saso L, Valesini G. Specific oxidative stress parameters differently correlate with nailfold capillaroscopy changes and organ involvement in systemic sclerosis. Clin Rheumatol. 2008;27(2):225-30.
93. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol. 2007;39(1):44-84.
94. Kuschel L, Hansel A, Schonherr R, Weissbach H, Brot N, Hoshi T, Heinemann SH. Molecular cloning and functional expression of a human peptide methionine sulfoxide reductase (hMsrA). FEBS Lett. 1999;456(1):17-21.
95. Ogawa F, Sander CS, Hansel A, Oehrl W, Kasperczyk H, Elsner P, Shimizu K, Heinemann SH, Thiele JJ. The repair enzyme peptide methionine-S-sulfoxide reductase is expressed in human epidermis and upregulated by UVA radiation. J Invest Dermatol. 2006;126(5):1128-34.
96. Prentice HM, Moench IA, Rickaway ZT, Dougherty CJ, Webster KA, Weissbach H. MsrA protects cardiac myocytes against hypoxia/reoxygenation induced cell death. Biochem Biophys Res Commun. 2008;366(3):775-8.
97. Ogawa F, Shimizu K, Hara T, Muroi E, Komura K, Takenaka M, Hasegawa M, Fujimoto M, Takehara K, Sato S. Autoantibody against one of the antioxidant repair enzymes, methionine sulfoxide reductase A, in systemic sclerosis: association with pulmonary fibrosis and vascular damage. Arch Dermatol Res. 2010;302(1):27-35.
98. Erickson JR, Joiner ML, Guan X, Kutschke W, Yang J, Oddis CV, Bartlett RK, Lowe JS, O'Donnell SE, Aykin-Burns N, Zimmerman MC, Zimmerman K, Ham AJ, Weiss RM, Spitz DR, Shea MA, Colbran RJ, Mohler PJ, Anderson ME. A dynamic pathway for calcium-independent activation of CaMKII by methionine oxidation. Cell. 2008;133(3):462-74.
99. Baroni SS, Santillo M, Bevilacqua F, Luchetti M, Spadoni T, Mancini M, Fraticelli P, Sambo P, Funaro A, Kazlauskas A, Avvedimento EV, Gabrielli A. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med. 2006;354(25):2667-76.
100. Edelberg JM, Lee SH, Kaur M, Tang L, Feirt NM, McCabe S, Bramwell O, Wong SC, Hong MK. Platelet-derived growth factor-AB limits the extent of myocardial infarction in a rat model: feasibility of restoring impaired angiogenic capacity in the aging heart. Circulation. 2002;105(5):608-13.
101. Eming SA, Krieg T. Molecular mechanisms of VEGF-A action during tissue repair. J Invest Dermatol. 2006;11(1):79-86.
102. Davies CA, Jeziorska M, Freemont AJ, Herrick AL. The differential expression of VEGF, VEGFR-2, and GLUT-1 proteins in disease subtypes of systemic sclerosis. Hum Pathol. 2006;37(2):190-7.
103. Higley H, Persichitte K, Chu S, Waegell W, Vancheeswaran R, Black C. Immunocytochemical localization and serologic detection of transforming growth factor beta 1. Association with type I procollagen and inflammatory cell markers in diffuse and limited systemic sclerosis, morphea, and Raynaud's phenomenon. Arthritis Rheum. 1994;37(2):278-88.
104. Mackiewicz Z, Sukura A, Povilenaite D, Ceponis A, Virtanen I, Hukkanen M, Konttinen YT. Increased but imbalanced expression of VEGF and its receptors has no positive effect on angiogenesis in systemic sclerosis skin. Clin Exp Rheumatol. 2002;20(5):641-6.
105. Gill M, Dias S, Hattori K, Rivera ML, Hicklin D, Witte L, Girardi L, Yurt R, Himel H, Rafii S. Vascular trauma induces rapid but transient mobilization of VEGFR2(+)AC133(+) endothelial precursor cells. Circ Res. 2001;88(2):167-74.
106. Kuwana M, Okazaki Y, Yasuoka H, Kawakami Y, Ikeda Y. Defective vasculogenesis in systemic sclerosis. Lancet. 2004;364(9434):603-10.
107. Cipriani P, Guiducci S, Miniati I, Cinelli M, Urbani S, Marrelli A, Dolo V, Pavan A, Saccardi R, Tyndall A, Giacomelli R, Cerinic MM. Impairment of endothelial cell differentiation from bone marrow-derived mesenchymal stem cells: new insight into the pathogenesis of systemic sclerosis. Arthritis Rheum. 2007;56(6):1994-2004.
108. Cutolo M, Pizzorni C, Sulli A. Nailfold video-capillaroscopy in systemic sclerosis. Z Rheumatol. 2004;63(6):457-62.
109. Simons M. Angiogenesis: where do we stand now? Circulation. 2005;111(12):1556-66.
110. Simons M, Ware JA. Therapeutic angiogenesis in cardiovascular disease. Nat Rev Drug Discov. 2003;2(11):863-71.
111. Lu H, Dhanabel M, Volk R, Waterman MJ, Ramchandran R, Knebelmann B, Segal M, Sukhatme VP. Kringle 5 causes cell cycle arrest and apoptosis of endothelial cells. Biochem Biophys Res Commun. 1999;258(3):668-73.
112. Staton CA. Angiogenesis inhibitors found within the haemostasis pathway. J Cell Mol Med. 2005;9(2):286-302.
113. Wigley FM, Flavahan NA. Raynaud's phenomenon. Rheum Dis Clin North Am. 1996;22(4):765-81.
114. Pepper MS. Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler Thromb Vasc Biol. 2001;21(7):1104-17.
115. Keck RG, Berleau L, Harris R, Keyt BA. Disulfide structure of the heparin binding domain in vascular endothelial growth factor: characterization of posttranslational modifications in VEGF. Arch Biochem Biophys. 1997;344(1):103-13.
116. Ihn H. The role of TGF-beta signaling in the pathogenesis of fibrosis in scleroderma. Arch Immunol Ther Exp. 2002;50(5):325-31.
117. Jinnin M, Ihn H, Mimura Y, Asano Y, Yamane K, Tamaki K. Effects of hepatocyte growth factor on the expression of type I collagen and matrix metalloproteinase-1 in normal and scleroderma dermal fibroblasts. J Invest Dermatol. 2005;124(2):324-30.
118. Lijnen HR, Ugwu F, Bini A, Collen D. Generation of an angiostatin-like fragment from plasminogen by stromelysin-1 (MMP-3). Biochemistry. 1998;37(14):4699-702.
119. O'Reilly MS, Wiederschain D, Stetler-Stevenson WG, Folkman J, Moses MA. Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance. J Biol Chem. 1999;274(41):29568-71.
120. Weihrauch D, Xu H, Shi Y, Wang J, Brien J, Jones DW, Kaul S, Komorowski RA, Csuka ME, Oldham KT, Pritchard KA. Effects of D-4 F on vasodilation, oxidative stress, angiostatin, myocardial inflammation, and angiogenic potential in tight-skin mice. Am J Physiol. 2007;293(3):H1432-41.
121. Vassalli JD, Baccino D, Belin D. A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J Cell Biol. 1985;100(1):86-92.
122. Wei Y, Waltz DA, Rao N, Drummond RJ, Rosenberg S, Chapman HA. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem. 1994;269(51):32380-8.
123. D'Alessio S, Fibbi G, Cinelli M, Guiducci S, Del Rosso A, Margheri F, Serrati S, Pucci M, Kahaleh B, Fan P, Annunziato F, Cosmi L, Liotta F, Matucci-Cerinic M, Del Rosso M. Matrix metalloproteinase 12-dependent cleavage of urokinase receptor in systemic sclerosis microvascular endothelial cells results in impaired angiogenesis. Arthritis Rheum. 2004;50(10):3275-85.
124. Margheri F, Manetti M, Serrati S, Nosi D, Pucci M, Matucci-Cerinic M, Kahaleh B, Bazzichi L, Fibbi G, Ibba-Manneschi L, Del Rosso M. Domain 1 of the urokinase-type plasminogen activator receptor is required for its morphologic and functional, beta2 integrin-mediated connection with actin cytoskeleton in human microvascular endothelial cells: failure of association in systemic sclerosis endothelial cells. Arthritis Rheum. 2006;54(12):3926-38.
125. Giusti B, Serrati S, Margheri F, Papucci L, Rossi L, Poggi F, Magi A, Del Rosso A, Cinelli M, Guiducci S, Kahaleh B, Matucci-Cerinic M, Abbate R, Fibbi G, Del Rosso M. The antiangiogenic tissue kallikrein pattern of endothelial cells in systemic sclerosis. Arthritis Rheum. 2005;52(11):3618-28.
126. Del Rosso A, Distler O, Milia AF, Emanueli C, Ibba-Manneschi L, Guiducci S, Conforti ML, Generini S, Pignone A, Gay S, Madeddu P, Matucci-Cerinic M. Increased circulating levels of tissue kallikrein in systemic sclerosis correlate with microvascular involvement. Ann Rheum Dis. 2005;64(3):382-7.
127. Bhoola KD, Figueroa CD, Worthy K. Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev. 1992;44(1):1-80.
128. Plendl J, Snyman C, Naidoo S, Sawant S, Mahabeer R, Bhoola KD. Expression of tissue kallikrein and kinin receptors in angiogenic microvascular endothelial cells. Biol Chem. 2000;381(11):1103-15.
129. Emanueli C, Madeddu P. Targeting kinin receptors for the treatment of tissue ischaemia. Trends Pharmacol Sci. 2001;22(9):478-84.
130. Giusti B, Fibbi G, Margheri F, Serrati S, Rossi L, Poggi F, Lapini I, Magi A, Del Rosso A, Cinelli M, Guiducci S, Kahaleh B, Bazzichi L, Bombardieri S, Matucci-Cerinic M, Gensini GF, Del Rosso M, Abbate R. A model of anti-angiogenesis: differential transcriptosome profiling of microvascular endothelial cells from diffuse systemic sclerosis patients. Arthritis Res Ther. 2006;8(4):R115.
131. Allt G, Lawrenson JG. Pericytes: cell biology and pathology. Cells Tissues Organs. 2001;169(1):1-11.
132. Sima AA, Chakrabarti S, Garcia-Salinas R, Basu PK. The BB-rat-an authentic model of human diabetic retinopathy. Curr Eye Res. 1985;4(10):1087-92.
133. Sims DE. Recent advances in pericyte biology-implications for health and disease. Can J Cardiol. 1991;7(10):431-43.
134. Mandarino LJ, Sundarraj N, Finlayson J, Hassell HR. Regulation of fibronectin and laminin synthesis by retinal capillary endothelial cells and pericytes in vitro. Exp Eye Res. 1993;57(5):609-21.
135. Hirschi KK, D'Amore PA. Control of angiogenesis by the pericyte: molecular mechanisms and significance. EXS. 1997;79:419-28.
136. Herman IM, D'Amore PA. Microvascular pericytes contain muscle and nonmuscle actins. J Cell Biol. 1985;101(1):43-52.
137. Edelman DA, Jiang Y, Tyburski J, Wilson RF, Steffes C. Pericytes and their role in microvasculature homeostasis. J Surg Res. 2006;135(2):305-11.
138. Hirschi KK, Rohovsky SA, D'Amore PA. PDGF, TGF-beta, and heterotypic cell-cell interactions mediate endothelial cell-induced recruitment of 10 T1/2 cells and their differentiation to a smooth muscle fate. J Cell Biol. 1998;141(3):805-14.
139. Kelley C, D'Amore P, Hechtman HB, Shepro D. Microvascular pericyte contractility in vitro: comparison with other cells of the vascular wall. J Cell Biol. 1987;104(3):483-90.
140. Tilton RG, Kilo C, Williamson JR. Pericyte-endothelial relationships in cardiac and skeletal muscle capillaries. Microvasc Res. 1979;18(3):325-35.
141. Cuevas P, Gutierrez-Diaz JA, Reimers D, Dujovny M, Diaz FG, Ausman JI. Pericyte endothelial gap junctions in human cerebral capillaries. Anat Embryol (Berl). 1984;170(2):155-9.
142. Miller FN, Sims DE. Contractile elements in the regulation of macromolecular permeability. Fed Proc. 1986;45(2):84-8.
143. Murphy DD, Wagner RC. Differential contractile response of cultured microvascular pericytes to vasoactive agents. Microcirculation. 1994;1(2):121-8.
144. Shepro D, Morel NM. Pericyte physiology. FASEB J. 1993;7(11):1031-8.
145. Carmeliet P. Blood vessels and nerves: common signals, pathways and diseases. Nat Rev Genet. 2003;4(9):710-20.
146. Louissaint Jr A, Rao S, Leventhal C, Goldman SA. Coordinated interaction of neurogenesis and angiogenesis in the adult songbird brain. Neuron. 2002;34(6):945-60.
147. Palmer TD, Willhoite AR, Gage FH. Vascular niche for adult hippocampal neurogenesis. J Comp Neurol. 2000;425(4):479-94.
148. Ronnov-Jessen L, Petersen OW, Koteliansky VE, Bissell MJ. The origin of the myofibroblasts in breast cancer. Recapitulation of tumor environment in culture unravels diversity and implicates converted fibroblasts and recruited smooth muscle cells. J Clin Invest. 1995;95(2):859-73.
149. Sundberg C, Ivarsson M, Gerdin B, Rubin K. Pericytes as collagen-producing cells in excessive dermal scarring. Lab Invest. 1996;74(2):452-66.
150. Sundberg C, Ljungstrom M, Lindmark G, Gerdin B, Rubin K. Microvascular pericytes express platelet-derived growth factor-beta receptors in human healing wounds and colorectal adenocarcinoma. Am J Pathol. 1993;143(5):1377-88.
151. Rajkumar VS, Sundberg C, Abraham DJ, Rubin K, Black CM. Activation of microvascular pericytes in autoimmune Raynaud's phenomenon and systemic sclerosis. Arthritis Rheum. 1999;42(5):930-41.
152. Jelaska A, Korn JH. Role of apoptosis and transforming growth factor beta1 in fibroblast selection and activation in systemic sclerosis. Arthritis Rheum. 2000;43(10):2230-9.
153. Sappino AP, Masouye I, Saurat JH, Gabbiani G. Smooth muscle differentiation in scleroderma fibroblastic cells. Am J Pathol. 1990;137(3):585-91.
154. Rajkumar VS, Howell K, Csiszar K, Denton CP, Black CM, Abraham DJ. Shared expression of phenotypic markers in systemic sclerosis indicates a convergence of pericytes and fibroblasts to a myofibroblast lineage in fibrosis. Arthritis Res Ther. 2005;7(5):R1113-23.
155. Frid MG, Dempsey EC, Durmowicz AG, Stenmark KR. Smooth muscle cell heterogeneity in pulmonary and systemic vessels. Importance in vascular disease. Arterioscler Thromb Vasc Biol. 1997;17(7):1203-9.
156. Gittenberger-de Groot AC, DeRuiter MC, Bergwerff M, Poelmann RE. Smooth muscle cell origin and its relation to heterogeneity in development and disease. Arterioscler Thromb Vasc Biol. 1999;19(7):1589-94.
157. Owens GK. Molecular control of vascular smooth muscle cell differentiation. Acta Physiol Scand. 1998;164(4):623-35.
158. Rhodes JM, Simons M. The extracellular matrix and blood vessel formation: not just a scaffold. J Cell Mol Med. 2007;11(2):176-205.
159. Davis GE, Saunders WB. Molecular balance of capillary tube formation versus regression in wound repair: role of matrix metalloproteinases and their inhibitors. J Investig Dermatol Symp Proc. 2006;11(1):44-56.
160. Davis GE, Senger DR. Endothelial extracellular matrix: biosynthesis, remodeling, and functions during vascular morphogenesis and neovessel stabilization. Circ Res. 2005;97(11):1093-107.
161. Senger DR. Molecular framework for angiogenesis: a complex web of interactions between extravasated plasma proteins and endothelial cell proteins induced by angiogenic cytokines. Am J Pathol. 1996;149(1):1-7.
162. Vernon RB, Sage EH. Between molecules and morphology. Extracellular matrix and creation of vascular form. Am J Pathol. 1995;147(4):873-83.
163. Dvorak HF, Nagy JA, Berse B, Brown LF, Yeo KT, Yeo TK, Dvorak AM, van de Water L, Sioussat TM, Senger DR. Vascular permeability factor, fibrin, and the pathogenesis of tumor stroma formation. Ann N Y Acad Sci. 1992;667:101-11.
164. Dvorak HF, Senger DR, Dvorak AM. Fibrin as a component of the tumor stroma: origins and biological significance. Cancer Metastasis Rev. 1983;2(1):41-73.
165. Nagy JA, Brown LF, Senger DR, Lanir N, Van de Water L, Dvorak AM, Dvorak HF. Pathogenesis of tumor stroma generation: a critical role for leaky blood vessels and fibrin deposition. Biochim Biophys Acta. 1989;948(3):305-26.
166. Werb Z. ECM and cell surface proteolysis: regulating cellular ecology. Cell. 1997;91(4):439-42.
167. Cheresh DA, Berliner SA, Vicente V, Ruggeri ZM. Recognition of distinct adhesive sites on fibrinogen by related integrins on platelets and endothelial cells. Cell. 1989;58(5):945-53.
168. Suehiro K, Gailit J, Plow EF. Fibrinogen is a ligand for integrin alpha5beta1 on endothelial cells. J Biol Chem. 1997;272(8):5360-6.
169. Sahni A, Altland OD, Francis CW. FGF-2 but not FGF-1 binds fibrin and supports prolonged endothelial cell growth. J Thromb Haemost. 2003;1(6):1304-10.
170. Sahni A, Francis CW. Plasmic degradation modulates activity of fibrinogen-bound fibroblast growth factor-2. J Thromb Haemost. 2003;1(6):1271-7.
171. Bobik A, Tkachuk V. Metalloproteinases and plasminogen activators in vessel remodeling. Curr Hypertens Rep. 2003;5(6):466-72.
172. Garcia-Touchard A, Henry TD, Sangiorgi G, Spagnoli LG, Mauriello A, Conover C, Schwartz RS. Extracellular proteases in atherosclerosis and restenosis. Arterioscler Thromb Vasc Biol. 2005;25(6):1119-27.
173. Davis GE, Pintar Allen KA, Salazar R, Maxwell SA. Matrix metalloproteinase-1 and-9 activation by plasmin regulates a novel endothelial cell-mediated mechanism of collagen gel contraction and capillary tube regression in three-dimensional collagen matrices. J Cell Sci. 2001;114(Pt 5):917-30.
174. Saunders WB, Bayless KJ, Davis GE. MMP-1 activation by serine proteases and MMP-10 induces human capillary tubular network collapse and regression in 3D collagen matrices. J Cell Sci. 2005;118(Pt 10):2325-40.
175. Giannelli G, Iannone F, Marinosci F, Lapadula G, Antonaci S. The effect of bosentan on matrix metalloproteinase-9 levels in patients with systemic sclerosis-induced pulmonary hypertension. Curr Med Res Opin. 2005;21(3):327-32.
176. Kim WU, Min SY, Cho ML, Hong KH, Shin YJ, Park SH, Cho CS. Elevated matrix metalloproteinase-9 in patients with systemic sclerosis. Arthritis Res Ther. 2005;7(1):R71-9.
177. Distler O, Distler JH, Scheid A, Acker T, Hirth A, Rethage J, Michel BA, Gay RE, Muller-Ladner U, Matucci-Cerinic M, Plate KH, Gassmann M, Gay S. Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ Res. 2004;95(1):109-16.
178. Avouac J, Wipff J, Goldman O, Ruiz B, Couraud PO, Chiocchia G, Kahan A, Boileau C, Uzan G, Allanore Y. Angiogenesis in systemic sclerosis: impaired expression of vascular endothelial growth factor receptor 1 in endothelial progenitor-derived cells under hypoxic conditions. Arthritis Rheum. 2008;58(11):3550-61.
179. Silverstein JL, Steen VD, Medsger Jr TA, Falanga V. Cutaneous hypoxia in patients with systemic sclerosis (scleroderma). Arch Dermatol. 1988;124(9):1379-82.
180. Manalo DJ, Rowan A, Lavoie T, Natarajan L, Kelly BD, Ye SQ, Garcia JG, Semenza GL. Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood. 2005;105(2):659-69.
181. Kahaleh MB. The role of vascular endothelium in fibroblast activation and tissue fibrosis, particularly in scleroderma (systemic sclerosis) and pachydermoperiostosis (primary hypertrophic osteoarthropathy). Clin Exp Rheumatol. 1992;10(Suppl 7):51-6.
182. Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol. 2002;3(5):349-63.
183. Lauber K, Bohn E, Krober SM, Xiao YJ, Blumenthal SG, Lindemann RK, Marini P, Wiedig C, Zobywalski A, Baksh S, Xu Y, Autenrieth IB, Schulze-Osthoff K, Belka C, Stuhler G, Wesselborg S. Apoptotic cells induce migration of phagocytes via caspase-3-mediated release of a lipid attraction signal. Cell. 2003;113(6):717-30.
184. Holmes A, Abraham DJ, Chen Y, Denton C, Shi-wen X, Black CM, Leask A. Constitutive connective tissue growth factor expression in scleroderma fibroblasts is dependent on Sp1. J Biol Chem. 2003;278(43):41728-33.
185. Shi-Wen X, Leask A, Abraham D. Regulation and function of connective tissue growth factor/CCN2 in tissue repair, scarring and fibrosis. Cytokine Growth Factor Rev. 2008;19(2):133-44.
186. Anderson ME, Allen PD, Moor T, Hillier V, Taylor CJ, Herrick AL. Computerized Nailfold Video Capillaroscopy-A New Tool for Assessment of Raynaud's Phenomenon. J Rheumatol. 2005;32:841-8.
187. Brown GE, O'Leary PA. Skin capillaries in scleroderma. Arch Intern Med. 1925;36:73-88.
188. Maricq HR, LeRoy EC. Patterns of finger capillary abnormalities in connective tissue disease by 'wide-field' microscopy. Arthritis Rheum. 1973;16:619-28.
189. Blann AD, Illinworth K, Jayson MIV. Mechanisms of endothelial damage in systemic sclerosis and Raynaud's phenomenon. J Rheumatol. 1993;20:1325-30.
190. Carpentier PH, Maricq HR. Microvasculature in systemic sclerosis. Rheum Dis Clin North Am. 1990;16:75-91.
191. Bukhari M, Herrick AL, Moore T, Manning J, Jayson MIV. Increased nailfold capillary dimensions in primary Raynaud's phenomenon and systemic sclerosis. Br J Rheumatol. 1996;35:1127-31.
192. Meli M, Gitzelmann G, Koppensteiner R, Amann-Vesti BR. Predictive value of nailfold capillaroscopy in patients with Raynaud's phenomenon. Clin Rheumatol. 2006;25:153-8.
193. Miniati I, Guiducci S, Conforti ML, Rogai V, Fiori G, Cinelli M, Saccardi R, Guidi S, Bosi A, Tyndall A, Matucci-Cerinic M. Autologous stem cell transplantation improves microcirculation in systemic sclerosis. Ann Rheum Dis. 2009;68:94-8.
194. Albrecht HP, Hiller D, Hornstein OP, Buhler-Singer S, Muck M, Gruschwitz M. Microcirculatory functions in systemic sclerosis: additional parameters for therapeutic concepts? J Invest Dermatol. 1993;101(2):211-5.
195. Lee P, Sarkozi J, Bookman AA, Keystone EC, Armstrong SK. Digital blood flow and nailfold capillary microscopy in Raynaud's phenomenon. J Rheumatol. 1986;13(3):564-9.
196. Mourad JJ, Priollet P, Girerd X, Safar M, Lazareth I, Laurent S. The wall to lumen ratio of the radial artery in patients with Raynaud's phenomenon. J Vasc Res. 1997;34(4):298-305.
197. Keberle M, Tony HP, Jahns R, Hau M, Haerten R, Jenett M. Assessment of microvascular changes in Raynaud's phenomenon and connective tissue disease using color doppler ultrasound. Rheumatology (Oxford). 2000;39(11):1206-13.
198. Englehart M, Kristensen JK. Raynaud's phenomenon: blood supply to fingers during indirect cooling, evaluated by laser Doppler flowrometry. Clin Physiol. 1986;6(6):481-8.
199. Pistorius MA, Planchon B, deFaucal P. Plethysmographic cold test for diagnosis and evaluation of the severity of Raynaud's phenomenon. Validation of the method by factorial analysis of correspondence in 541 patients. Int Angiol. 1994;13(1):10-4.
200. Goodfield M, Hume A, Rowell N. Reactive hyperemic responses in systemic sclerosis patients and healthy controls. J Invest Dermatol. 1989;93(3):368-7.
201. Wigley FM, Wise RA, Mikdashi J, Schaefer S, Spence RJ. The post-occlusive hyperemic response in patients with systemic sclerosis. Arthritis Rheum. 1990;33(11):1620-5.
202. Wollersheim H, Reyenga J, Thien T. Laser Doppler velocimetry of fingertips during heat provocation in normals and in patients with Raynaud's phenomenon. Scand J Clin Lab Invest. 1988;48(1):91-5.
203. Wan MC, Moore T, Hollis S, Herrick AL. Ankle brachial pressure index in systemic sclerosis: influence of disease subtype and anticentromere antibody. Rheumatology (Oxford). 2001;40(10):1102-5.
204. Hahn M, Heubach T, Steins A, Junger M. Hemodynamics in manifold capillaries of patients with systemic scleroderma: synchronous measurements of capillary blood pressure and red blood cell velocity. J Invest Dermatol. 1998;110(6):982-5.
205. Kristensen JK. Blood flow and blood pressure in fingers in generalized scleroderma. Int J Dermatol. 1982;21(7):404-6.
206. Maricq HR, Valter I, Maricq JC. An objective method to estimate the severity of Raynaud's phenomenon: digital blood pressure response to cooling. Vasc Med. 1998;3(2):109-13.
207. Clark S, Hollis S, Campbell F, Moore T, Jayson M, Herrick A. The "distal-dorsal difference" as a possible predictor of secondary Raynaud's phenomenon. J Rheumatol. 1999;26(5):1128-8.
208. Salem Mel-S, el-Girby AH, el-Moneim NA, Khalil SA. Value of finger arterial blood pressure in diagnosis of vascular changes in some connective tissue diseases. Angiology. 1993;44(3):183-7.
209. Valentini G, Leonardo G, Moles DA, Apaia MR, Maselli R, Tirri G, Del Guercio R. Transcutaneous oxygen pressure in systemic sclerosis:evaluation at different sensor temperatures and relationship to skin perfusion. Arch Dermatol Res. 1991;283(5):285-8.
210. Hahn M, Hahn C, Brauer K, Junger M. Skin thermoregulation during local cooling in healthy volunteers and patients with systemic sclerosis-synchronous assessment of capillary red blood cell velocity, laser Doppler flux and skin temperature. Vasa. 1998;27(1):3-9.
211. Christner PJ, Jimenez SA. Animal models of systemic sclerosis: insights into systemic sclerosis pathogenesis and potential therapeutic approaches. Curr Opin Rheumatol. 2004;16(6):746-52.
212. Smith GP, Chan ESL. Molecular pathogenesis of skin fibrosis: insight from animal models. Curr Rheumatol Rep. 2010;12:26-33.
213. Marie I, Beny JL. Endothelial dysfunction in murine model of systemic sclerosis: tight-skin mice 1. J Invest Dermatol. 2002;119:1379-87.
214. Sgonc R. The vascular perspective of systemic sclerosis: of chickens, mice and men. Int Arch Allergy Immunol. 1999;120:169-76.
215. Ruzek MC, Jha S, Ledbetter S, Richards SM, Garman RD. A modified model of graft-versus-host-induced systemic sclerosis (scleroderma) exhibits all major aspects of the human disease. Arthritis Rheum. 2004;50:1319-31.
216. Asano Y, Stawski L, Hant F, Highland K, Silver R, Szalai G, Watson DK, Trojanowska M. Endothelial Fli1 deficiency impairs vascular homeostasis: a role in scleroderma vasculopathy. Am J Pathol. 2010;176:1983-98.
217. Maurer B, Busch N, Jüngel A, Pileckyte M, Gay RE, Michel BA, Schett G, Gay S, Distler J, Distler O. Transcription factor fos-related antigen-2 induces progressive peripheral vasculopathy in mice closely resembling human systemic sclerosis. Circulation. 2009;120(23):2367-76.
218. Cutolo M, Sulli A, Secchi ME, Paolino S, Pizzorni C. Nailfold capillaroscopy is useful for the diagnosis and follow-up of autoimmune rheumatic diseases. A future tool for the analysis of microvascular heart involvement? Rheumatology 2006;45(suppl 4):iv43-iv46.